The Team

Dr. Mahler is CEO & Board Member at ten23 health. He previously led the Drug Product Services (DPS) Business Unit at Lonza AG (2015-2021) and worked in various leadership roles such as Head Pharmaceutical Development & Supplies at Roche (2005-2015) and at Merck KGaA (2000-2005). He has an extensive expertise in formulation development, process development & validation, packaging/device development and integration, sterile manufacturing, and regulatory submissions with numerous IND/IMPD and BLAs.

He studied Pharmacy at the University of Mainz, Germany, holds a Ph.D. in toxicology from the Institute of Pharmacy, University of Mainz, and pharmacist specialization degrees in Toxicology & Ecology, and Pharmaceutical Technology. He has also was further trained Business and Marketing (Akad).

Hanns-Christian obtained his venia legendi (German Habilitation) from the University of Frankfurt, Germany, in 2010 and is adjunct faculty member and lecturer at the universities of Frankfurt and Basel.

He was elected an AAPS Fellow in November 2013, nominated extraordinary Professor for Pharmaceutical Technology in November 2015 and received the PDA Distinguished Service Award in 2018.

He is on the boards of Bionter AG and KriyaBio SA. Furthermore, he serves as Editor for Pharmaceutical Research, Journal of Pharmaceutical Sciences, AAPS Open Journal, and PDA Journal of Pharmaceutical Sciences & Technology. Hanns-Christian has published more than 120 manuscripts and is co-inventor of more than 50 patents.

Dr. Jörg is Chief Customer Delivery Officer (COO) at ten23 health. She was previously Head of Pharmaceutical Development, Drug Product Services (DPS) at Lonza AG (2016-2021), acting also ad interim as Manufacturing Site Head in Stein and Business Unit Head DPS.

Before that she worked in various leadership roles such as Head Early Phase Pharmaceutical development at Novartis AG (2006-2016). She has over 15 years of experience in formulation development, process development, transfer and validation, sterile manufacturing and regulatory submissions for early-, late-stage and life-cycle parenteral dosage forms.

She studied Pharmacy at the University of Mainz, Germany, and holds a Ph.D. in pharmaceutical technology from the Ludwig-Maximilians-Universität (LMU), Munich, Germany, that was performed in a research collaboration with Merck KGA, developing high-concentration antibody formulations.

Dr. Gert Reinwald is Chief Quality Officer (CQO) at ten23 health.

He joined from Elanco Inc. where he held several Global Quality leadership roles, such as Senior Director Quality External Manufacturing or Executive Director External Manufacturing and Internal Sites.

Before that he worked in various leadership roles at Roche, such as Director Manufacturing, Director Quality/Site Quality Head or as Technical Transfer lead.

Dr. Reinwald was honorary board member of the Swiss Society of Industrial Pharmacists from 2017-2022, supporting young talents from the universities of Zuerich and Muttenz.

He studied Pharmacy at the University of Heidelberg, Germany, and earned his Ph.D. from the  University of Wuerzburg, Germany.

Mr. Wilmink is CPO at ten23 health. He previously worked in Business & Organizational Development at Galloping Hills and Opinity BV, as mediator and coach, as Head of Global HR at Lonza (2011-2017), Director Human Resources Europe at Schering Plough (2002-2007) and other management roles.

JanBart studied HR & organizational behavior at the Hogeschool West Brabant, Netherlands, holds a Master’s degree in eclectic psychology (IEP), and is a Certified Coach Practitioner.

Amrith Kiran is currently leading Talent Acquisition at ten23 health. After an established career in Operations, she advanced into human resource management within life sciences, and is managing talents globally.

Amrith holds a master's in psychology and postgraduate diploma in human resources management.

Patrick Klassnitz is Head of Finance at ten23 health. 

He previously worked for 13 years at Thermo Fisher Scientifc, most recentlyas Sr. Director Finance, Clinical Trial Division EMEA, and Managing Directorat the Clinical Packaging site in Allschwil. Prior to that, he worked for 5 years at Ernst Young Accounting Services, Basel, Switzerland.

Patrick has done a commercial apprenticeship at the Commercial Business School, Liestal, Switzerland, and during his time at EY the further education as Swiss Certified Fiduciary at the Swiss Fiduciary School, Switzerland.

Dr. Allmendinger is CSO at ten23 health (starting in November 2021). She is also Adjunct Professor and Group Leader at the University of Freiburg, researching novel parenteral drug formulations and device solutions to improve stability, usability, and cost of goods.

From 2010 to 2021, she worked at Roche as Principal Scientist, Pharmaceutical Development. She worked inter alia on manufacturability and injectability of high-concentration formulations, syringe and high-volume drug/device combination products, particulates and surfactant strategy.

Andrea studied Pharmacy at the University of Heidelberg, Germany, and the University College London, UK, and holds a Ph.D. in Pharmaceutical Sciences from the University of Basel, Switzerland. She obtained the venia legendi (German Habilitation) from the University of Freiburg, Germany, in 2021, and also serves as Editor-In-Chief for AAPS Open Journal.

Dr. Van der Heide is responsible for Sales and worked previously as Chief Business officer at Pivot Park Screening Centre BV (2020-2021). Before that, he has been working in the pharmaceutical / pharmaceutical supply industry for over 25 years, in sales, business development and business management, at Lonza AG (2002-2020), DSBG Ltd. (2001-2002) and other companies.

Teun studied Organic and Analytical Chemistry at the Vrije Universiteit in Amsterdam, the Netherlands, and he obtained his PhD in Organic Synthesis from the same university.

Dr. Carole Schanté is Fairstainability Officer at ten23 health. She is also founder and consultant at “Engage to Act”, promoting employee engagement for environmental sustainability.

She previously worked as an Environmental Specialist at Novartis AG after starting as a Protein Formulation Scientist.

Carole studied Pharmaceutical Engineering and holds a Ph.D. in Pharmaceutical Sciences and Pharmaceutical Chemistry from the Université de Strasbourg, France. Her postdoctoral research was on the characterization and stabilization of vaccines and proteins at the Kansas University, Lawrence, USA.

She is also Ambassador for Basel for the Zero Waste Switzerland organization.

Tamara Hell is Diversity, Inclusion & LGBTQ+ Officer and Drug Product Scientist at ten23 health. She is also CFO and Assistant to the CEO at MiHKAL GmbH, Allschwil.

She previously worked at Lonza AG as Lead Scientist in Bioanalytics, asBioassay Lead at NBE Therapeutics AG and as Lab Professional at Novartis Pharma AG, all in Basel, Switzerland. She completed an apprenticeship as Biology Laboratory Technician and is currently studying for the Advanced Federal Diploma of Higher Education at aprentas.

Creixell Espilla-Gilart is Chief Marketing Officer at ten23 health.

Creixell is responsible for ten23’s strategic marketing and worked previously as Team Leader Marketing for the aerospace trade show ILA Berlin at Messe Berlin (2019-2023). Before that, she worked at the PDA - Parenteral Drug Association (2011-2019) in different positions, her last as Marketing Lead for Europe.

Creixell holds a master’s degree in History of Art by the Universitat de Lleida (Spain) and a MBA for cultural enterprises from the Dresden International University (Germany).

Mara Willa is leading External Communication and Media relations at ten23 health. Prior the acquisition of swissfillon by ten23 health, she was working for digital marketing agencies in Zurich and Geneva. She is also Founder and Freelancer at the Kardamon Agentur, Crans-Montana, Switzerland.

Mara holds a bilingual Masters degree in Business Communication.

Richard joined 3i in 2007 and is co-Head of 3i’s North American Private Equity team and Global Head of Healthcare. He focuses on Healthcare and Industrials and has been involved in 3i’s investments in ten23 health, SaniSure, Cirtec Medica, Quintiles, Q Holding, Dynatect Manufacturing and Mold-Masters. He currently sits on the Boards of ten23 health, SaniSure, Q Holding, Dynatect Manufacturing and Cirtec Medical, and previously sat on the Boards of Quintiles and Mold-Masters. Prior to joining 3i, Richard was a Principal at Halyard Capital, where he invested in companies in the media, business services and communications sectors. Prior to joining Halyard, Richard was an Associate at Entrade, where he invested in technology and internet infrastructure businesses. Richard began his career at Security Capital's Preferred Growth Private Equity fund. He is actively involved in several non-profit organisations and is the Chairman of the New York Private Equity Network. Richard received a BA in Economics from Williams College.

Nikhil joined 3i in 2016 in the New York office and is a member of 3i’s Healthcare sector coverage team. He participates in all elements of the investment process, including industry segment analysis, identification and screening of new opportunities, due diligence, transaction structuring, financing and execution. He currently sits on the Board of ten23 health, SaniSure, Q Holding and Cirtec Medical.

Prior to joining 3i, Nikhil was a Vice President at Chicago Pacific Founders, where he was an integral member of a debut middle market private equity fund and participated in the acquisition of three portfolio companies. Prior to joining CPF, Nikhil was a Senior Associate at Water Street Healthcare Partners, a mid-market private equity firm with approximately $2 billion of capital under management. While at Water Street, he helped execute a number of platform investments and successful portfolio company exits.

Nikhil was previously an Analyst in the Global Healthcare Investment Banking division of UBS Investment Bank. Nikhil graduated from New York University’s Leonard Stern School of Business with Honours.

Dr. Redeker is a senior executive with a proven track record in the pharmaceutical and diagnostics industry. She previously spent over 15 years in various leadership roles at Roche, including Global Head of Non-Clinical Safety & Technical Sciences, Head Technical Development Biologics and spokesperson of the Executive Board, Roche Diagnostics GmbH. She has also served on the Boards of the Germanic Cancer Research Center and EIT Health. She is currently a  Board member of  ABB AG, Germany, Smart4Diagnostics and the Academic Advisory Council of the University of Heidelberg. 

Ursula studied Chemistry and obtained her Ph.D. at the University of Bonn (Germany) and a Master’s degree from the University of California, Santa Barbara (USA).